$ATXI
Avenue Therapeutics Inc Stock $atxi

$atxi Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000143774923031621 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.137M	$1.160M	$469.0K
YoY Change	-66.23%	147.33%	-21.04%
% of Gross Profit
Research & Development	$982.0K	$907.0K	$194.0K
YoY Change	227.33%	367.53%	-30.22%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.119M	$907.0K	$194.0K
YoY Change	606.33%	367.53%	-30.22%
Operating Profit		-$2.068M	-$663.0K
YoY Change		211.92%	-23.97%
Interest Expense	$22.00K	$10.00K	$1.000K
YoY Change	-99.5%	900.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	$2.714M	$2.581M	$1.000K
YoY Change	-51.36%	258000.0%
Pretax Income	$617.0K	$510.0K	-$662.0K
YoY Change	17.75%	-177.04%	-24.0%
Income Tax
% Of Pretax Income
Net Earnings	$640.0K	$513.0K	-$662.0K
YoY Change	11.3%	-177.49%	-24.0%
Net Earnings / Revenue
Basic Earnings Per Share		$0.06	-$0.45
Diluted Earnings Per Share	$0.03	$0.06	-$0.45
COMMON SHARES
Basic Shares Outstanding	13.25M	8.183M	22.13M
Diluted Shares Outstanding		8.200M	1.466M

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.783M	$160.0K	$217.0K
YoY Change	-73.42%	-26.27%	-62.91%
Cash & Equivalents	$1.783M	$161.0K	$217.0K
Short-Term Investments
Other Short-Term Assets	$67.00K	$330.0K	$358.0K
YoY Change	-51.09%	-7.82%	1134.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.850M	$500.0K	$575.0K
YoY Change	-72.97%	-13.04%	-16.42%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$2.000K	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$1.850M	$500.0K	$575.0K
Total Long-Term Assets	$0.00	$2.000K	$0.00
Total Assets	$1.850M	$502.0K	$575.0K
YoY Change	-72.97%	-12.7%	-16.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$78.00K	$296.0K	$364.0K
YoY Change	-39.53%	-18.68%	80.2%
Accrued Expenses	$532.0K	$1.430M	$250.0K
YoY Change	-15.96%	472.0%	-61.3%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.196M	$5.024M	$614.0K
YoY Change	-66.58%	718.24%	-27.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.196M	$5.024M	$614.0K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.196M	$5.024M	$614.0K
YoY Change	-66.58%	718.24%	-27.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$90.90M	-$91.60M	-$81.10M
YoY Change	12.78%	12.95%	6.57%
Common Stock	$3.000K	$1.000K	$81.09M
YoY Change	-100.0%	-100.0%	6.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.582M	-$3.650M	-$39.00K
YoY Change
Total Liabilities & Shareholders Equity	$1.850M	$502.0K	$575.0K
YoY Change	-72.97%	-12.7%	-16.42%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	$640.0K	$513.0K	-$662.0K
YoY Change	11.3%	-177.49%	-24.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$2.324M	-$890.0K	-$554.0K
YoY Change	-44.26%	60.65%	3.36%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$1.000M
YoY Change
Cash From Investing Activities	$0.00	-$1.000M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.946M	480.0K	-119.0K
YoY Change	-62.98%	-503.36%
NET CHANGE
Cash From Operating Activities	-2.324M	-890.0K	-554.0K
Cash From Investing Activities	0.000	-1.000M
Cash From Financing Activities	3.946M	480.0K	-119.0K
Net Change In Cash	1.622M	-1.410M	-673.0K
YoY Change	-75.01%	109.51%	25.56%
FREE CASH FLOW
Cash From Operating Activities	-$2.324M	-$890.0K	-$554.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80551000	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8964222
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8964222
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4773841
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4773841
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38114
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4113275
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1111 Kane Concourse, Suite 301
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bay Harbor Islands
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33154
	dei	City Area Code CityAreaCode	781
	dei	Local Phone Number LocalPhoneNumber	652‑4500
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	ATXI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13247622
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	161000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6708000	usd
CY2023Q3	atxi	Deferred Financing Costs DeferredFinancingCosts	310000	usd
CY2022Q4	atxi	Deferred Financing Costs DeferredFinancingCosts	0	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	137000	usd
CY2023Q3	us-gaap	Assets Assets	502000	usd
CY2022Q4	us-gaap	Assets Assets	6845000	usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3300000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2609000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5024000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3579000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	5024000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3579000	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	87917000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84456000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91568000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3650000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3905000	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-872000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-639000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4522000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3266000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	502000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6845000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	907000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	194000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5149000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2153000	usd
CY2023Q3	atxi	Research And Development Expense For Licenses Acquired ResearchAndDevelopmentExpenseForLicensesAcquired	0	usd
CY2022Q3	atxi	Research And Development Expense For Licenses Acquired ResearchAndDevelopmentExpenseForLicensesAcquired	0	usd
	atxi	Research And Development Expense For Licenses Acquired ResearchAndDevelopmentExpenseForLicensesAcquired	4230000	usd
	atxi	Research And Development Expense For Licenses Acquired ResearchAndDevelopmentExpenseForLicensesAcquired	0	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1161000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	469000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3042000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1978000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2068000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-663000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12421000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4131000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	9000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	104000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	usd
CY2023Q3	atxi	Financing Costs Warrant Liabilities FinancingCostsWarrantLiabilities	-0	usd
CY2022Q3	atxi	Financing Costs Warrant Liabilities FinancingCostsWarrantLiabilities	-0	usd
	atxi	Financing Costs Warrant Liabilities FinancingCostsWarrantLiabilities	332000	usd
	atxi	Financing Costs Warrant Liabilities FinancingCostsWarrantLiabilities	-0	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2572000	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1544000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-0	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2581000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1316000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	513000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-662000	usd
	us-gaap	Profit Loss ProfitLoss	-11105000	usd
	us-gaap	Profit Loss ProfitLoss	-4127000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13000	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-88000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	526000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-662000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11017000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4127000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.54
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.86
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.54
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.86
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8114155
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1465691
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7155050
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1441542
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8200069
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1465691
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7155050
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1441542
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6146000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	561000	usd
CY2023Q3	atxi	Stock Issued During Period Value License Expense StockIssuedDuringPeriodValueLicenseExpense	0	usd
CY2023Q3	atxi	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	526000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4522000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3266000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	599000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	72000	usd
	atxi	Stock And Prefunded Warrants Issued During Period Value Private Placement Net Of Issuance Costs StockAndPrefundedWarrantsIssuedDuringPeriodValuePrivatePlacementNetOfIssuanceCosts	866000	usd
	atxi	Stock Issued During Period Value License Expense StockIssuedDuringPeriodValueLicenseExpense	1230000	usd
	atxi	Stock Issued During Period Value Exercise0f Warrants StockIssuedDuringPeriodValueExercise0fWarrants	0	usd
	atxi	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-88000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11017000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4522000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	598000	usd
CY2022Q3	atxi	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-662000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-39000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3451000	usd
	atxi	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	637000	usd
	us-gaap	Profit Loss ProfitLoss	-4127000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-39000	usd
	us-gaap	Profit Loss ProfitLoss	-11105000	usd
	us-gaap	Profit Loss ProfitLoss	-4127000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	599000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	637000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1544000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	atxi	Issuance Of Stock For Licenses Acquired IssuanceOfStockForLicensesAcquired	1230000	usd
	atxi	Issuance Of Stock For Licenses Acquired IssuanceOfStockForLicensesAcquired	0	usd
	atxi	Research And Development License Acquried Expense ResearchAndDevelopmentLicenseAcquriedExpense	3000000	usd
	atxi	Research And Development License Acquried Expense ResearchAndDevelopmentLicenseAcquriedExpense		usd
	atxi	Issuance Of Stock Under Founders Agreement IssuanceOfStockUnderFoundersAgreement	72000	usd
	atxi	Issuance Of Stock Under Founders Agreement IssuanceOfStockUnderFoundersAgreement	0	usd
	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	13000	usd
	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	-90000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-119000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-87000	usd
	atxi	Increase Decrease In Deferred Financing Costs IncreaseDecreaseInDeferredFinancingCosts	-239000	usd
	atxi	Increase Decrease In Deferred Financing Costs IncreaseDecreaseInDeferredFinancingCosts	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7127000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3427000	usd
	atxi	Payments To Acquire Research And Development Licenses PaymentsToAcquireResearchAndDevelopmentLicenses	3000000	usd
	atxi	Payments To Acquire Research And Development Licenses PaymentsToAcquireResearchAndDevelopmentLicenses	-0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	atxi	Issuance Of Common Stock Prefund Warrants And Warrants IssuanceOfCommonStockPrefundWarrantsAndWarrants	3101000	usd
	atxi	Issuance Of Common Stock Prefund Warrants And Warrants IssuanceOfCommonStockPrefundWarrantsAndWarrants	0	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	550000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	71000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	119000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3580000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-119000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6547000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3546000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6708000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3763000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	161000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	217000	usd
	atxi	Unpaid Deferred Financing Costs UnpaidDeferredFinancingCosts	239000	usd
	atxi	Unpaid Deferred Financing Costs UnpaidDeferredFinancingCosts	219000	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91600000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company's consolidated financial statements include certain amounts that are based on management's best estimates and judgements. The Company's significant estimates include, but are <em style="font: inherit;">not</em> limited to, fair value of warrants, stock-based compensation, common stock issued to acquire licenses, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results <em style="font: inherit;"> may </em>differ from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	413000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1460000	usd
CY2019Q4	atxi	Contractual Obligation Development Expense ContractualObligationDevelopmentExpense	81500000	usd
CY2019Q4	atxi	Contractual Obligation Commercial Expense ContractualObligationCommercialExpense	151000000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	296000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	129000	usd
CY2023Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	230000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	199000	usd
CY2023Q3	atxi	Accrued Contingent Fee AccruedContingentFee	0	usd
CY2022Q4	atxi	Accrued Contingent Fee AccruedContingentFee	208000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	934000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	262500000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	949000	usd
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7877935
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29811
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1685000000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.14
	atxi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grands In Period Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrandsInPeriodWeightedAverageRemainingContractualTerm	P10Y
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	-0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	-0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1685000000
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.14
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y8M12D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1422500000
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.14
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y8M12D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.14
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y8M12D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1200000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.249	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.257	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.041	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	98137
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2.6
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	561000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	599000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	637000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4137916
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.3
CY2022	atxi	Class Of Warrant Or Right Aggregate Intrinsic Value ClassOfWarrantOrRightAggregateIntrinsicValue	1000	usd
CY2023Q1	atxi	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	3432598
CY2023Q1	atxi	Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights	0.88
CY2023Q1	atxi	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	400083
CY2023Q1	atxi	Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights	0
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7170431
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.32
CY2023Q1	atxi	Class Of Warrant Or Right Aggregate Intrinsic Value ClassOfWarrantOrRightAggregateIntrinsicValue	1272000	usd
CY2023Q2	atxi	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	1092299
CY2023Q2	atxi	Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights	0
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6078132
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.55
CY2023Q2	atxi	Class Of Warrant Or Right Aggregate Intrinsic Value ClassOfWarrantOrRightAggregateIntrinsicValue	1000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6078132
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.55
CY2023Q3	atxi	Class Of Warrant Or Right Aggregate Intrinsic Value ClassOfWarrantOrRightAggregateIntrinsicValue	1000	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	550000	usd

Files In Submission

Name	View Source	Status
atxi-20230930_cal.xml	Edgar Link	unprocessable
0001437749-23-031621-index-headers.html	Edgar Link	pending
0001437749-23-031621-index.html	Edgar Link	pending
0001437749-23-031621.txt	Edgar Link	pending
0001437749-23-031621-xbrl.zip	Edgar Link	pending
atxi-20230930.xsd	Edgar Link	pending
atxi20230930_10q.htm	Edgar Link	pending
ex_563737.htm	Edgar Link	pending
ex_563738.htm	Edgar Link	pending
ex_563739.htm	Edgar Link	pending
ex_563740.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
atxi-20230930_def.xml	Edgar Link	unprocessable
atxi-20230930_lab.xml	Edgar Link	unprocessable
atxi-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
atxi20230930_10q_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATXI
Avenue Therapeutics Inc Stock $atxi

2023 Q4 Form 10-Q Financial Statement

#000143774923031621 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATXI Avenue Therapeutics Inc Stock $atxi

2023 Q4 Form 10-Q Financial Statement

#000143774923031621 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATXI
Avenue Therapeutics Inc Stock $atxi